Bioassay Laboratory (BL) at Translational Health Science and Technology Institute (THSTI) is a core facility supporting development of vaccines and therapeutics. BL is part of the centralized network of laboratories of CEPI (Coalition for Epidemic Preparedness Innovations) for facilitating COVID-19 vaccine development. BL is also accredited by NABL (National Accreditation Board for Testing and Calibration Laboratories) as per ISO 17025:2017 standard and is the only facility in a DBT institute offering accredited assays services to vaccine developers. The primary objective of bioassay laboratory is to develop and provide assay platforms to vaccine developers for assessment of vaccine candidates as per the global standards. As a core facility of THSTI, bioassay laboratory supports both academia and industry in a collaborative mode for vaccine and antiviral development.
THSTI Bioassay Laboratory is committed to data integrity and rigor through continual improvements in the quality of assays and maintaining, highest ethical standards. This will be achieved by our total commitment to:
The facility is involved in collaborations with both national and international organizations such as International Centre for Genetic Engineering and Biotechnology, New Delhi; Indian Institute of Science and National Centre for Biological Sciences, Bengaluru; Christian Medical College, Vellore; Manipal Virus Research Centre; National Institute of Virology, Pune. We have supported both national and international vaccine manufacturers such as Biological E. Ltd, India; S K Bioscience, South Korea; Litevax, Netherlands; Medigen Vaccine Biologics Corp, Taiwan; Nanogen, Vietnam; The Government Pharmaceutical Organization (GPO), Thailand; Aurum Institute, South Africa.